See separate instructions.

## Part I Reporting Issuer

1 Issuer's name			2 Issuer's employer identification number (EIN)						
CYPRIUM THERAPEU	TICS. INC.		47-1202840						
		4 Telephone	4 Telephone No. of contact		5 Email address of contact				
DAVID JIN		212-574-2810			DJIN@FORTRESSBIOTECH.COM				
6 Number and street	(or P.O. box if mail is not	t	7 City, town, or post office, state, and ZIP code of contact						
1111 KANE CONCOURSE, SUITE 301					BAY HARBOR ISLANDS, FL 33154				
8 Date of action 9 Classification and description									
SEE STATEMENT 1			ABLE PERPETUAL PREFERRED STOCK						
10 CUSIP number	11 Serial number	(s)	12 Ticker symbol		13 Account number(s)				
N/A	N/A	N/A			N/A				
Part II Organiz	ational Action Attac	ch additional	statements if needed	. See ba	ck of form for additional questions.				
14 Describe the orga	inizational action and, if a	applicable, the	date of the action or the	e date aga	inst which shareholders' ownership is measured for				
the action NON APRIL 30 2024, MAY 31, 2024, AND JUNE 30, 2024, CYPRIUM THERAPEUTICS, INC. ("CYPRIUM")									
					ETUAL PREFERRED STOCK ("SERIES A				
PREFERRED STOCK")	) SHAREHOLDERS.								
SHAREHOLDERS WHO	O WERE HOLDERS OF	SERIES A PR	EFERRED STOCK AS	OF THE C	LOSE OF BUSINESS ON APRIL 15, 2024,				
MAY 15, 2024, AND JU	INE 15, 2024, RESPECT	IVELY, THE R	ECORD DATES, WERE	ELIGIBL	E TO RECEIVE CASH				
	0.1953125 FOR EVERY								

15 Describe the quantitative effect of the organizational action on the basis of the security in the hands of a U.S. taxpayer as an adjustment per share or as a percentage of old basis ► CYPRIUM PAID CASH DISTRIBUTIONS OF \$0.1953125 PER SHARE OF SERIES A PREFERRED

STOCK ON APRIL 30 2024, MAY 31, 2024, AND JUNE 30 2024. CYPRIUM DOES NOT HAVE ACCUMULATED EARNINGS AND PROFITS ("AE&P") AS OF JANUARY 1, 2024 AND DOES NOT BELIEVE IT WILL HAVE CURRENT YEAR E&P ("CE&P") BASED ON THE LATEST FINANCIALS AVAILABLE. HOWEVER, 2024 CE&P CANNOT BE FINALLY DETERMINED UNTIL THE 2024 TAX YEAR IS CLOSED. IF CYPRIUM LATER DETERMINES THAT IT HAS 2024 CE&P, CYPRIUM WILL FILE A CORRECTED FORM 8937.

AS SUCH, AS OF THE DATE OF THIS FILING, CYPRIUM BELIEVES THE DISTRIBUTIONS DESCRIBED ABOVE CONSTITUTE A RETURN OF CAPITAL TO THE EXTENT OF THE SHAREHOLDER'S TAX BASIS. TO THE EXTENT THAT THE DISTRIBUTION EXCEEDS THE SHAREHOLDER'S TAX BASIS, THE SHAREHOLDER MAY BE REQUIRED TO RECOGNIZE A TAXABLE GAIN.

16 Describe the calculation of the change in basis and the data that supports the calculation, such as the market values of securities and the valuation dates ► <u>THE SHAREHOLDER'S TAX BASIS IS REDUCED BY \$0.1953125</u>, <u>MULTIPLIED BY THE NUMBER OF SHARES OF</u> <u>SERIES A PREFERRED STOCK THE SHAREHOLDER OWNS</u>.

## Part II Organizational Action (continued)

17 List the applicable Internal Revenue Code section(s) and subsection(s) upon which the tax treatment is based ► INTERNAL REVENUE CODE IRC SECTIONS 301(c), 316(a) AND 1016.

 18 Can any resulting loss be recognized?
 THE DISTRIBUTION ON A PER SHARE BASIS SHOULD REDUCE THE SHAREHOLDER'S TAX

 BASIS OF EACH SHARE HELD ON THE DATE OF DISTRIBUTION. UPON DISPOSITION OF ALL OR A PORTION OF THE SHARES,

 THE SHAREHOLDER SHOULD RECOGNIZE GREATER TAX GAIN OR LESS TAX LOSS.

19 Provide any other information necessary to implement the adjustment, such as the reportable tax year ► THE REPORTABLE TAX YEAR FOR THE DISTRIBUTION FOR EACH SHAREHOLDER IS THE TAXABLE YEAR THAT INCLUDES DECEMBER 31, 2024.

THE INFORMATION CONTAINED ON THIS FORM DOES NOT CONSTITUTE TAX ADVICE. SHAREHOLDERS OF SERIES A PREFERRED STOCK ARE URGED TO CONSULT THEIR OWN TAX ADVISORS WITH RESPECT TO THEIR INDIVIDUAL TAX CONSEQUENCES OF THE DISTRIBUTIONS.

	Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.								
Sign Here	Signa	ture David Jin	Date▶ _ 7/15/24						
	Print	your name ► DAVID JIN		Title TREASUR	ER				
Paid		Print/Type preparer's name	Preparer's signature	Date	Check 🗌 if	PTIN			
Prepa	rer	MITCHELL CLARINE	Mitchell Clarine	7/10/2024	self-employed	P01883317			
Use Or		Firm's name	Firm's EIN 🕨	46-4311251					
		Firm's address  ONE WASHINGTON ST	Phone no.	310-820-1025					
Send Form 8937 (including accompanying statements) to: Department of the Treasury, Internal Revenue Service, Ogden, UT 84201-0054									

Cyprium Therapeutics, Inc. FEIN: 47-1202840 Attachment to and Made Part of Form 8937

**PART I: Reporting Issuer** 

Box 9 Date of action:

April 30 2024, May 31, 2024, and June 30, 2024.